Navigation Links
Encouraging results in pancreatic cancer research

Researchers at SUNY Downstate Medical Center and the Brooklyn VA Hospital have found that when a human protein, PNC-28, is administered to pancreatic tumor cells in animals, the tumors are destroyed. The research was reported in the October 1st edition of the International Journal of Cancer.

Matthew R. Pincus, MD, PhD, professor of pathology at SUNY Downstate and chairman of pathology and laboratory medicine at the Brooklyn VA, said, "The results are very encouraging. PNC-28 may be an effective agent in treating cancers, especially if delivered directly to the tumor."

PNC-28 is a p53 peptide, a naturally occurring human protein known to suppress tumor growth. The researchers previously found that PNC-28 induces death of a variety of human tumor cell lines, including a pancreatic cancer cell line, while not harming healthy cells.

The research team has now given PNC-28 to laboratory animals to test its ability to block the growth of pancreatic cancer cells. When administered over a two-week period in the peritoneal cavities of mice containing simultaneously transplanted tumors, PNC-28 caused complete destruction of these tumors.

When delivered concurrently with tumor implantation, PNC-28 completely blocked tumor growth during the two-week period of administration and two weeks post-treatment, followed by weak tumor growth that leveled off at low tumor sizes.

In addition, according to Josef Michl, MD, associate professor of pathology at SUNY Downstate, "When administered from a site distant from the tumor, PNC-28 still caused a decrease in tumor size. This tumor growth was significantly slower than growth in the presence of a control peptide."

Dr. Pincus added that this peptide and its parent peptide, called PNC-27, are lethal to a wide variety of human cancer cells, besides pancreatic cancer, including colon, breast, cervical and bone (osteogenic sarcoma) cancers. These peptides kill cancer cells that do not even contain native p53 protein and therefore appear to have a wide applicability in treating a variety of human cancers.
'"/>

Source:SUNY Downstate Medical Center


Related biology news :

1. Gene vaccine for Alzheimers disease shows promising results
2. Roche clinical trial registry and results database launched
3. Diabetic nerve therapy shows striking results
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. New results validating Pall prion reduction filter disclosed at ISBT Congress
6. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
7. Combination therapy shows promising results in patients with advanced lung cancer
8. Vaccine for brain tumors shows promising results
9. Artificial cornea offers better results for infants, some blind patients
10. The eyes have it -- Autism research yields surprising results
11. UCSF brain tumor vaccine trial shows promising results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2016)... 18, 2016  Extenua Inc., a pioneering developer ... use and access of ubiquitous on-premise and cloud ... American Cyber.  ... transformational C4ISR and Cyber initiatives in support of ... proven technology solutions," said Steve Visconti , ...
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
(Date:1/11/2016)... JOSE, Calif. , Jan. 11, 2016 ... of human interface solutions, today announced that its ClearPad ... driver integration (TDDI) products won two separate categories in ... Best Mobile Innovator and Best Technology Breakthrough. The Synaptics ... system cost, a simplified supply chain, thinner devices, brighter ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... Feb.10, 2016 ASAE is introducing a hybrid ... Companies (AMC) the option of joining or renewing through ... determined by staff size, every employee in any size ... and reap all available member benefits.   ... organizational membership options will allow organizations of any size ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a ... promotion of two long-standing principal investigators (PI) to the roles of Chief Medical ... Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, ...
(Date:2/10/2016)... ... 10, 2016 , ... Curoverse announced today that the open-source, ... capabilities for managing and processing genomic and health data at petabyte scale. ... and analyzing genomic data,” said Adam Berrey chief executive officer at Curoverse. “Microsoft ...
(Date:2/9/2016)... LITTLE FALLS, N.J. , Feb. 9, 2016 ... ), a biotechnology company specializing in the development ... the health of damaged tissues and organs, recently ... milestones for the first quarter of 2016. ... Regenicin began the new 2015 fiscal year in ...
Breaking Biology Technology: